Tome Biosciences

Tome Biosciences is a biotechnology startup founded in 2021 with the goal of shaping the future of genomic medicine. Positioned as "The final chapter in genomic medicine," Tome Biosciences is on a mission to deliver cures to patients through cell and integrative gene therapies. The company specializes in programmable genomic integration (PGI) and boasts technologies enabling the insertion of any genetic sequence of any size at any location in the genome with site-specific precision.

In December 2023, Tome Biosciences secured a considerable $213.00M Series A investment from a notable group of investors, including Arch Venture Partners, GV, Longwood Fund, Polaris Partners, Andreessen Horowitz/a16z, Alexandria Venture Investments, Fujifilm, and Bruker. This significant backing highlights both the innovative potential of Tome Biosciences and the confidence of industry-leading investors in the company's vision and technology. Based in the United States, Tome Biosciences is poised to make a substantial impact in the biotechnology space with its pioneering approach to genomic medicine.